USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes98% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$15 – $696
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your tamiflu prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about oseltamivir. Some of the dosage forms listed on this page may not apply to the brand name Tamiflu.
Common side effects of Tamiflu include: nausea and vomiting. Other side effects include: abdominal pain. See below for a comprehensive list of adverse effects.
Applies to oseltamivir: oral capsule, oral powder for suspension
Along with its needed effects, oseltamivir (the active ingredient contained in Tamiflu) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking oseltamivir:
Incidence not known
Some side effects of oseltamivir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to oseltamivir: oral capsule, oral powder for reconstitution
The most common side effects were nausea and vomiting.
The most common side effects reported with this drug during studies for the treatment of influenza were nausea, vomiting, and headache; the most common side effects reported in prophylaxis studies were nausea, vomiting, headache, and pain. Most side effects were reported on a single occasion, occurred on the first or second day of therapy, and resolved spontaneously within 1 to 2 days.
Very common (10% or more): Headache (up to 17%)
Common (1% to 10%): Dizziness, vertigo
Frequency not reported: Drowsiness
Postmarketing reports: Seizure/convulsion
Side effects with similar or higher incidence among placebo patients included dizziness and vertigo.
Very common (10% or more): Nausea
Common (1% to 10%): Vomiting, diarrhea, abdominal pain, upper abdominal pain, dyspepsia
Frequency not reported: Pseudomembranous colitis
Postmarketing reports: Gastrointestinal bleeding, hemorrhagic colitis
Side effects with similar or higher incidence among placebo patients included diarrhea, abdominal pain, upper abdominal pain, and dyspepsia.
Common (1% to 10%): Nasal congestion, cough, sore throat, bronchitis, nasopharyngitis, upper respiratory tract infections, influenza, rhinorrhea, sinusitis
Frequency not reported: Pneumonia, peritonsillar abscess, congestion, rhinitis, dry sore throat, epistaxis, asthma, aggravated asthma
Side effects with similar or higher incidence among placebo patients included cough, nasal congestion, sore throat, rhinorrhea, bronchitis, sinusitis, nasopharyngitis, upper respiratory tract infections, and influenza.
Common (1% to 10%): Insomnia
Frequency not reported: Mania
Postmarketing reports: Abnormal behavior, delirium, altered level of consciousness, confusion, delusions, hallucinations, agitation, anxiety, nightmares, self-injury
Influenza can be associated with various neurologic and behavioral symptoms (including hallucinations, delirium, abnormal behavior), with fatal outcomes in some cases; such events may occur with encephalitis or encephalopathy but can occur without obvious severe disease. There are postmarketing reports (mostly in Japan) of delirium and abnormal behavior leading to injury, with fatal outcomes in some cases, in influenza patients using this drug. Although frequency is unknown, based on usage, these events appear uncommon. These events were primarily reported in pediatric patients, often with abrupt onset and rapid resolution. The contribution of this drug to such events has not been established.
Side effects with similar or higher incidence among placebo patients included insomnia.
Side effects with similar or higher incidence among placebo patients included fatigue, pyrexia, influenza-like illness, and pain in limb.
Common (1% to 10%): Fatigue, pain, pyrexia, influenza-like illness, pain in limb, otitis media, earache
Uncommon (0.1% to 1%): Tympanic membrane disorder
Frequency not reported: Humerus fracture, malaise, sepsis, facial edema, ear disorder, accidental injury
Postmarketing reports: Hypothermia
Side effects with similar or higher incidence among placebo patients included herpes simplex.
Common (1% to 10%): Herpes simplex
Uncommon (0.1% to 1%): Dermatitis (including allergic and atopic dermatitis)
Rare (less than 0.1%): Angioneurotic edema
Postmarketing reports: Rash, urticaria, eczema, serious skin reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme
Common (1% to 10%): Back pain, arthralgia, myalgia
Side effects with similar or higher incidence among placebo patients included back pain, arthralgia, and myalgia.
Side effects with similar or higher incidence among placebo patients included dysmenorrhea.
Common (1% to 10%): Dysmenorrhea
Common (1% to 10%): Conjunctivitis (including red eyes, eye discharge, eye pain)
Postmarketing reports: Visual disturbances
Uncommon (0.1% to 1%): Elevated liver enzymes
Rare (less than 0.1%): Hepatic failure, fulminant hepatitis (including fatalities)
Frequency not reported: Hepatic function disorder, jaundice
Postmarketing reports: Hepatitis, abnormal liver function tests
Postmarketing reports: Hypersensitivity reactions (e.g., allergic skin reactions), allergy, anaphylactic/anaphylactoid reactions, swelling of the face or tongue
Uncommon (0.1% to 1%): Cardiac arrhythmia
Frequency not reported: Unstable angina, sudden cardiopulmonary arrest
Postmarketing reports: Arrhythmia
Frequency not reported: Hyperglycemia
Postmarketing reports: Aggravation of diabetes
Frequency not reported: Anemia, pancytopenia, lymphadenopathy
Postmarketing reports: Thrombocytopenia
April 24, 2020
April 23, 2020
April 22, 2020
April 10, 2020
July 9, 2020
July 1, 2020